Previous 10 | Next 10 |
2024-05-15 07:45:41 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics gets $125M in financing from Hercules Capital Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Qu...
2024-05-15 07:36:21 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Quan...
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE ); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHE...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
2024-05-14 13:24:59 ET More on Adaptimmune Adaptimmune: Huge Opportunity Amid Their Setback With Genentech Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune falls as Roche strategic collaboration ends Seeking Alpha’s Quan...
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended ...
2024-04-26 11:00:11 ET Summary Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Th...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-12 08:53:13 ET More on Adaptimmune Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript Adaptimmune: Drug Approval Now Imminent? FDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4 Seeking Alpha’s Quant Rating...
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4 th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18 th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. -...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma pa...
2024-05-31 16:15:02 ET Wells Fargo analyst issues EQUAL-WEIGHT recommendation for ADAP on May 31, 2024 02:43PM ET. The previous analyst recommendation was Equal-Weight. ADAP was trading at $1.135 at issue of the analyst recommendation. The overall analyst consensus : BUY...